ElizabethR.PlimackMDMS
Oncology • Philadelphia, PAGenitourinary Oncology
Chief, Division of Genitourinary Medical Oncology. Director, Genitourinary Clinical Research. Associate Professor, Department of Hematology/Oncology.
Dr. Plimack is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
333 Cottman Ave
Fox Chase Cancer Center
Philadelphia, PA 19111Phone+1 215-728-6900Fax+1 215-728-3639
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
NYU Grossman School of MedicineResidency, Internal Medicine, 2002 - 2005- New York University School of MedicineClass of 2002
Certifications & Licensure
PA State Medical License 2008 - 2026
TX State Medical License 2005 - 2008
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
- Dose Dense MVAC for Muscle Invasive Bladder Cancer Start of enrollment: 2009 Dec 07
- Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma Start of enrollment: 2010 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).Daniel M Geynisman, Philip H Abbosh, Eric Ross, Matthew R Zibelman, Pooja Ghatalia
Journal of Clinical Oncology. 2025-03-20 - Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma.Miya B Hugaboom, Lena V Wirth, Kelly Street, Neil Ruthen, Opeyemi A Jegede
Cancer Discovery. 2025-02-24 - 3 citationsFirst and Second-line Treatments in Metastatic Renal Cell Carcinoma.Regina Barragan-Carrillo, Eddy Saad, Renee-Maria Saliby, Maxine Sun, Laurence Albiges
European Urology. 2025-02-01
Journal Articles
- Pan-Tumor Genomic Biomarkers for PD-1 Checkpoint Blockade–Based ImmunotherapyJonathan Cheng, Patrick A Ott, Elizabeth R Plimack, Antoni Ribas, Andrew Joe, Science Magazine
Press Mentions
Bladder Cancer Survival Better with Nivolumab Than Placebo in New AnalysisFebruary 21st, 2025- Adjuvant Nivolumab Boosts Survival Outcomes in Muscle-Invasive Bladder CancerFebruary 17th, 2025
- ASCO GU 2023: Update on Bladder-Sparing Treatment Trial: RETAIN BLADDERFebruary 15th, 2023
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
